Targeting mutated KRAS in the first-line therapy

Hideaki Ijichi

doi:10.1002/ctd2.291

Clinical and Translational Discovery ›› 2024, Vol. 4 ›› Issue (2) :e291 DOI: 10.1002/ctd2.291

COMMENTARY

Targeting mutated KRAS in the first-line therapy

Hideaki Ijichi ^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Hideaki Ijichi. Targeting mutated KRAS in the first-line therapy. Clinical and Translational Discovery, 2024, 4(2): e291 DOI:10.1002/ctd2.291

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21:159.

[2]	Drosten M, Guerra C, Barbacid M. Genetically engineered mouse models of K-Ras-driven lung and pancreatic tumors: validation of therapeutic targets. Cold Spring Har Perspect Med. 2018;8:a031542.

[3]	Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371-2381.

[4]	Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387:120-131.

[5]	Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med. 2021;384:2382-2393.

[6]	Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Eng J Med. 2023;389:2125-2139.

[7]	Kuboki Y, Fakih M, Strickler J, et al. Sotorasib with panitumumabu in chemotherapy-refractory KRAS^G12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024;30:265-270.

[8]	Desai J, Alonso G, Kim SH, et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024;30:271-278.

[9]	Kemp SB, Cheng N, Markosyan N, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13:298-311.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.